Incyte (INCY) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.38% |
| Dec 31, 2025 | 38.32% |
| Sep 30, 2025 | 25.16% |
| Jun 30, 2025 | -30.17% |
| Mar 31, 2025 | 19.03% |
| Dec 31, 2024 | 23.70% |
| Sep 30, 2024 | 2.83% |
| Jun 30, 2024 | -41.95% |
| Mar 31, 2024 | 7.05% |
| Dec 31, 2023 | 12.00% |
| Sep 30, 2023 | -5.78% |
| Jun 30, 2023 | 56.74% |
| Mar 31, 2023 | -47.86% |
| Dec 31, 2022 | 38.94% |
| Sep 30, 2022 | 41.03% |
| Jun 30, 2022 | 8.32% |
| Mar 31, 2022 | 26.52% |
| Dec 31, 2021 | 4.10% |
| Sep 30, 2021 | 21.77% |
| Jun 30, 2021 | 57.99% |
| Mar 31, 2021 | 16.14% |
| Dec 31, 2020 | 8.05% |
| Sep 30, 2020 | 88.15% |
| Jun 30, 2020 | 82.27% |
| Mar 31, 2020 | -172.05% |
| Dec 31, 2019 | 24.10% |
| Sep 30, 2019 | 57.63% |
| Jun 30, 2019 | 65.74% |
| Mar 31, 2019 | 47.20% |
| Dec 31, 2018 | 55.77% |
| Sep 30, 2018 | 79.56% |
| Jun 30, 2018 | 32.02% |
| Mar 31, 2018 | -3.37% |
| Dec 31, 2017 | -32.32% |
| Sep 30, 2017 | 31.67% |
| Jun 30, 2017 | 68.01% |
| Mar 31, 2017 | -26.13% |
| Dec 31, 2016 | 34.32% |
| Sep 30, 2016 | 32.13% |
| Jun 30, 2016 | 20.79% |
| Mar 31, 2016 | 33.28% |
| Dec 31, 2015 | 21.61% |
| Sep 30, 2015 | 17.73% |
| Jun 30, 2015 | 46.90% |
| Mar 31, 2015 | -15.38% |